Point72 Asset Management L.P. Has $2.74 Million Stock Position in Cryoport, Inc. (NASDAQ:CYRX)

Point72 Asset Management L.P. lowered its holdings in shares of Cryoport, Inc. (NASDAQ:CYRX) by 16.0% in the 4th quarter, HoldingsChannel reports. The firm owned 352,680 shares of the company’s stock after selling 67,220 shares during the period. Point72 Asset Management L.P.’s holdings in Cryoport were worth $2,744,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in CYRX. JPMorgan Chase & Co. grew its stake in Cryoport by 1,464.4% during the third quarter. JPMorgan Chase & Co. now owns 305,237 shares of the company’s stock worth $2,475,000 after purchasing an additional 285,726 shares during the period. Avanza Fonder AB acquired a new stake in Cryoport during the fourth quarter worth approximately $64,000. SG Americas Securities LLC grew its stake in Cryoport by 44.8% during the fourth quarter. SG Americas Securities LLC now owns 146,789 shares of the company’s stock worth $1,142,000 after purchasing an additional 45,430 shares during the period. Penbrook Management LLC grew its stake in Cryoport by 6.0% during the fourth quarter. Penbrook Management LLC now owns 52,570 shares of the company’s stock worth $409,000 after purchasing an additional 2,975 shares during the period. Finally, Rhumbline Advisers grew its stake in Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock worth $492,000 after purchasing an additional 1,764 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CYRX shares. Morgan Stanley decreased their target price on Cryoport from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Monday, May 5th. UBS Group raised their price objective on Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, April 1st. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a research note on Thursday, May 8th. Roth Mkm reissued a “buy” rating and issued a $15.00 price objective on shares of Cryoport in a research note on Tuesday, April 1st. Finally, Guggenheim reissued a “buy” rating and issued a $10.00 price objective on shares of Cryoport in a research note on Wednesday, April 16th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Cryoport Trading Up 2.4%

Shares of Cryoport stock opened at $6.74 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a 52 week low of $4.58 and a 52 week high of $12.11. The stock has a 50 day moving average price of $5.95 and a two-hundred day moving average price of $6.85. The stock has a market capitalization of $337.92 million, a PE ratio of -1.99 and a beta of 1.92.

Cryoport (NASDAQ:CYRX) last announced its earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The company had revenue of $41.04 million for the quarter, compared to analysts’ expectations of $56.19 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. As a group, equities analysts anticipate that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Activity at Cryoport

In related news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares of the company’s stock, valued at $4,814,359.71. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 19,830 shares of company stock valued at $118,353 over the last 90 days. Insiders own 10.00% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.